APA

Furie R. A., Leon G., Thomas M., Petri M. A., Chu A. D., Hislop C., Martin R. S. & Scheinberg M. A. (20151026). A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study. : Annals of the rheumatic diseases.

Chicago

Furie R A, Leon G, Thomas M, Petri M A, Chu A D, Hislop C, Martin R S and Scheinberg M A. 20151026. A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study. : Annals of the rheumatic diseases.

Harvard

Furie R. A., Leon G., Thomas M., Petri M. A., Chu A. D., Hislop C., Martin R. S. and Scheinberg M. A. (20151026). A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study. : Annals of the rheumatic diseases.

MLA

Furie R A, Leon G, Thomas M, Petri M A, Chu A D, Hislop C, Martin R S and Scheinberg M A. A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study. : Annals of the rheumatic diseases. 20151026.